Quantamental Technologies LLC acquired a new position in shares of Tricida Inc (NASDAQ:TCDA) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 1,000 shares of the company’s stock, valued at approximately $39,000.
A number of other hedge funds have also recently modified their holdings of the stock. Legal & General Group Plc purchased a new position in Tricida during the third quarter worth $54,000. Great West Life Assurance Co. Can purchased a new position in Tricida during the fourth quarter worth $71,000. SG Americas Securities LLC purchased a new position in Tricida during the first quarter worth $143,000. BNP Paribas Arbitrage SA grew its position in shares of Tricida by 1,586.2% in the first quarter. BNP Paribas Arbitrage SA now owns 4,030 shares of the company’s stock valued at $156,000 after purchasing an additional 3,791 shares during the period. Finally, Amundi Pioneer Asset Management Inc. purchased a new stake in shares of Tricida in the fourth quarter valued at $99,000. 70.10% of the stock is owned by hedge funds and other institutional investors.
In other news, Director Orbimed Advisors Llc purchased 225,000 shares of the stock in a transaction on Wednesday, April 3rd. The stock was purchased at an average price of $36.00 per share, with a total value of $8,100,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Sandra I. Coufal sold 2,000 shares of the business’s stock in a transaction dated Thursday, February 28th. The shares were sold at an average price of $23.04, for a total value of $46,080.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 143,822 shares of company stock valued at $4,242,654. Company insiders own 66.70% of the company’s stock.
Shares of NASDAQ:TCDA opened at $36.31 on Thursday. The firm has a market capitalization of $1.74 billion and a PE ratio of -7.83. The company has a quick ratio of 16.51, a current ratio of 8.30 and a debt-to-equity ratio of 0.24. Tricida Inc has a 52 week low of $19.43 and a 52 week high of $40.83.
Tricida (NASDAQ:TCDA) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.90) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.80) by ($0.10). On average, research analysts anticipate that Tricida Inc will post -3.34 earnings per share for the current fiscal year.
A number of brokerages have recently commented on TCDA. Zacks Investment Research raised Tricida from a “hold” rating to a “buy” rating and set a $42.00 price objective for the company in a research report on Saturday, March 30th. Empire lifted their price objective on Tricida from $37.00 to $58.00 in a research report on Monday, April 1st.
COPYRIGHT VIOLATION NOTICE: “Quantamental Technologies LLC Takes $39,000 Position in Tricida Inc (TCDA)” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2019/05/16/quantamental-technologies-llc-takes-39000-position-in-tricida-inc-tcda.html.
Tricida Company Profile
Tricida, Inc, a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). It has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis.
Read More: Put Option
Want to see what other hedge funds are holding TCDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tricida Inc (NASDAQ:TCDA).
Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.